FLT3 and acute myeloid leukemia: In patients with high or adverse-risk AML, use of hypomethylating agents azacytidine and decitabine, and FLT3 inhibitors such as gilteritinib, quizartinib, and sorafenib may be beneficial to lower relapse rates post-transplantation [22,93,105,106,107,108].